Skip to Main Content

Verve Therapeutics said Monday that its experimental gene-editing treatment for a common form of heart disease was placed on clinical hold by the Food and Drug Administration, potentially delaying an ongoing, early-stage clinical trial.

The Cambridge, Mass.-based biotech had submitted a request to the FDA in October to allow participants in the U.S. to receive the CRISPR-based treatment, called VERVE-101, as part of its clinical trial program.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment